Epicutaneous Allergen Desensitization With Controlled Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing desensitization methods for allergies, such as subcutaneous and sublingual immunotherapy, are costly, require medical supervision, have risks, and are less effective for certain allergens, while epicutaneous methods are not widely used due to their invasive nature and lack of standardization.
Innovation Solution
A method involving repeated and controlled application of allergens on the skin to induce a sustained inflammatory response, monitored and adjusted to promote a tolerogenic immune reaction without adjuvants, using devices like occlusive patches to ensure skin contact and reaction observation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If subcutaneous or sublingual immunotherapy is used, then desensitization effectiveness is improved, but treatment cost and medical supervision requirements increase
Solution Approach 1:
The patent enables patients to perform desensitization treatment at home using epicutaneous application of allergens to the skin, eliminating the need for medical professional supervision and specialized injection equipment. The treatment becomes a self-administered process using simple topical application methods.
Solution Approach 2:
The patent extracts the desensitization function from complex medical procedures (subcutaneous injections or sublingual tablets requiring clinical supervision) and implements it through simple epicutaneous allergen application, removing the need for sophisticated delivery systems and professional oversight.
2Ease of operation
If epicutaneous desensitization is used, then treatment accessibility and ease of use are improved, but standardization and control of inflammatory response are worsened
Solution Approach 1:
The patent incorporates monitoring of cutaneous inflammatory responses as feedback to adjust treatment parameters. By observing and measuring the inflammatory reaction at the application site, practitioners can standardize the treatment protocol and control the degree of desensitization achieved, ensuring consistency across different patients and treatment stages.
3Reliability
If conventional immunotherapy methods are used, then immune response modification is improved, but risk of severe allergic reactions and anaphylaxis increases
Solution Approach 1:
The patent converts the typically harmful cutaneous inflammatory response into a beneficial therapeutic mechanism. By deliberately inducing controlled local inflammation through epicutaneous allergen application, the treatment harnesses the inflammatory response to drive immune tolerance development, transforming what is usually a sign of allergy into the mechanism of cure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Achieves safe and effective desensitization by gradually converting the immune response to tolerance, reducing cutaneous reactivity and systemic allergic reactions, applicable to various allergens without adjuvants or skin preparation.
Implementation Method 1
using devices like occlusive patches to ensure skin contact and reaction observation
Data Source
AI summary
The present application relates to a method for desensitization of allergic patients. More specifically it relates to an epicutaneous desensitization method, applicable to any type of allergens and of patients. The method of the invention is essentially non-invasive and does not require the use of adjuvants. Further, it may be easily applied and monitored by the actual patient.